Neuraxis shares surge 10.59% intraday after securing AMA Category I CPT code for PENFS therapy.

Neuraxis surged 10.59% intraday after announcing the activation of a Category I CPT code for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy. The code, effective January 8, 2026, establishes a permanent reimbursement pathway for Neuraxis’ IB-Stim treatment, aligning with Medicare, Medicaid, and commercial insurers’ billing standards. The milestone, described as critical for commercial scalability and payer alignment, reflects broad clinical acceptance of the therapy and supports long-term revenue growth. Management emphasized the code’s role in enhancing reimbursement predictability and expanding patient access, reinforcing confidence in the company’s commercial trajectory. The news directly correlates with the sharp intraday rally, driven by optimism over improved market adoption and regulatory validation of its neuromodulation technology.